

Lupin's Pithampur Unit gets clearance by Health Canada

02 April 2018 | News

Following the review, Health Canada has maintained the compliant rating for Unit 2 at Pithampur (Indore) and has issued a revised 'Establishment License'



Pharma major Lupin Limited (Lupin) has announced the successful facility review carried out by Health Canada for its Pithampur Unit 2 (Indore) manufacturing facility.

Following the review, Health Canada has maintained the compliant rating for Unit 2 at Pithampur (Indore) and has issued a revised 'Establishment License'.

Commenting on the development, Nilesh Gupta, Managing Director, Lupin said: "Lupin is committed to maintaining truly global quality standards at our manufacturing units. The successful review by Health Canada is a significant milestone in that journey for Pithampur Unit 2 (Indore)."

For the financial year ended 31st March, 2017, Lupin's consolidated sales and Net profit stood at Rs. 171,198 million (USD 2.55 billion) and Rs. 25,575 million (USD 381 million) respectively.